Finance

Lists
PTKFY:OTCMKTS
PT Kalbe Farma Unsponsored Indonesia ADR
$8.78
+4.77%
(+0.40) 1D
Aug 10, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PTKFY...
Open
$8.78
High
$8.78
Low
$8.78
Mkt. cap
37.45T
Avg. vol.
650.00
Volume
855.00
52-wk high
$18.59
52-wk low
$7.63
Beta
0.05
Shares outstanding
234.07M
No. of employees
13K
Open
$8.78
High
$8.78
Low
$8.78
Mkt. cap
37.45T
Avg. vol.
650.00
Volume
855.00
52-wk high
$18.59
52-wk low
$7.63
Beta
0.05
Shares outstanding
234.07M
No. of employees
13K
Profile
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise. The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, with a distribution arm that reaches over one million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient. Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar. Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
About PT Kalbe Farma Unsponsored Indonesia ADR
CEO-
Employees12.8K
FoundedSep 10, 1966
Headquarters-
SectorPharmaceutical industry
Websitekalbe.co.id
Previous reportsAll values in IDR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in IDR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
8.91T
9.34T
9.68T
9.80T
Cost of goods sold
5.46T
5.92T
6.02T
6.25T
Cost of revenue
5.46T
5.92T
6.02T
6.25T
Research and development expenses
98.31B
160.88B
113.14B
122.60B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.51T
1.95T
2.23T
2.27T
Operating expense
2.60T
2.14T
2.33T
2.39T
Total operating expenses
8.06T
8.05T
8.36T
8.64T
Operating income
851.77B
1.28T
1.32T
1.16T
Other non operating income
-3.78B
-4.17B
-3.63B
-3.74B
EBT including unusual items
877.87B
1.30T
1.36T
1.19T
EBT excluding unusual items
888.55B
1.30T
1.36T
1.18T
Income tax expense
211.19B
252.81B
303.84B
271.57B
Effective tax rate
24.06%
19.41%
22.40%
22.80%
Other operating expenses
-7.23B
31.35B
-10.02B
2.13B
Net income
656.41B
1.03T
1.03T
890.54B
Net profit margin
7.37%
11.07%
10.63%
9.09%
Earnings per share
14.44
22.72
22.74
19.68
Interest and investment income
41.31B
40.43B
32.07B
43.61B
Interest expense
-9.69B
-5.77B
-4.61B
-6.78B
Net interest expenses
31.62B
34.66B
27.46B
36.83B
Depreciation and amortization charges
-
-
-
-
EBITDA
1.05T
1.47T
1.51T
1.20T
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps